Estudio para evaluar los eventos adversos, el cambio en la actividad de la enfermedad y cómo el ABBV-101 oral se mueve por el cuerpo en participantes adultos con neoplasias malignas de células B
Primer estudio en humanos para evaluar la seguridad, la farmacocinética y la eficacia preliminar del degradador BTK, ABBV-101, en participantes con neoplasias malignas de células B
Non-Hodgkin's lymphoma (NHL) is a cancer that arises from the transformation of normal B and T lymphocytes (white blood cells). The purpose of this study is to assess the safety, pharmacokinetics, and preliminary efficacy of ABBV-101 in adult participants in relapsed or refractory (R/R) non-Hodgkin's lymphomas: chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), diffuse large b-cell lymphoma (DLBCL), non-germinal center B cell (GCB) DLBCL, mantle cell lymphoma (MCL), follicular lymphoma (FL), marginal zone lymphoma (MZL), Waldenström macroglobulinemia (WM), or transformed indolent NHL. Adverse events will be assessed.
ABBV-101 is an investigational drug being developed for the treatment of NHL. This study is a dose escalation phase to determine the maximum administered dose (MAD)/Maximum tolerated dose (MTD) of ABBV-101. Approximately 200 adult participants with multiple NHL subtypes will be enrolled in the study in sites world wide.
Participants will receive escalating oral doses of ABBV-101, until the MAD/MTD is determined, as part of the approximately 88 month study duration.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, and side effects.
Descripción general del estudio
Estado
Estado
Condiciones
Condiciones
Intervención / Tratamiento
Intervención / Tratamiento
Tipo de estudio
Tipo de estudio
Inscripción (Actual)
Inscripción
Fase
Fase
- Fase 1
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Berlin, Alemania, 12203
- Charite Universitaetsklinikum Berlin - Campus Benjamin Franklin /ID# 257431
-
Hamburg, Alemania, 20246
- Universitaetsklinikum Hamburg-Eppendorf /ID# 264566
-
-
Baden-Wurttemberg
-
Ulm, Baden-Wurttemberg, Alemania, 89081
- Universitaetsklinikum Ulm /ID# 253742
-
-
Bavaria
-
Würzburg, Bavaria, Alemania, 97080
- Universitaetsklinikum Wuerzburg /ID# 254636
-
-
Mecklenburg-Vorpommern
-
Rostock, Mecklenburg-Vorpommern, Alemania, 18057
- Universitaetsmedizin Rostock /ID# 259657
-
-
Saarland
-
Homburg, Saarland, Alemania, 66424
- Universitaetsklinikum des Saarlandes /ID# 257435
-
-
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- University Health Network_Princess Margaret Cancer Centre /ID# 253483
-
-
Quebec
-
Montreal, Quebec, Canadá, H2X 3E4
- Centre Hospitalier De L'Universite De Montreal - Hopital Saint-Luc /ID# 253428
-
-
-
-
-
Barcelona, España, 08035
- Hospital Universitario Vall de Hebron /ID# 260447
-
Madrid, España, 28034
- Hospital Universitario Ramon y Cajal /ID# 260450
-
Madrid, España, 28040
- Hospital Universitario Fundacion Jimenez Diaz /ID# 253654
-
Madrid, España, 28050
- Hospital Universitario HM Sanchinarro /ID# 253655
-
Salamanca, España, 37711
- Hospital Universitario de Salamanca /ID# 253656
-
-
Madrid
-
Majadahonda, Madrid, España, 28222
- Hospital Universitario Puerta de Hierro - Majadahonda /ID# 260196
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85711
- Arizona Oncology - Tucson - Wilmot Road /ID# 252351
-
-
California
-
Orange, California, Estados Unidos, 92868-3201
- UC Irvine Medical Center /ID# 263020
-
Palo Alto, California, Estados Unidos, 94304
- Stanford University - Palo Alto /ID# 249683
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80012
- Rocky Mountain Cancer Centers - Aurora /ID# 252237
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60611
- Northwestern Medicine - Northwestern Memorial Hospital /ID# 249347
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215-5400
- Beth Israel Deaconess Medical Center /ID# 249302
-
-
New Jersey
-
New Brunswick, New Jersey, Estados Unidos, 08901
- Rutgers Cancer Institute of New Jersey /ID# 249323
-
-
New York
-
Albany, New York, Estados Unidos, 12206-5013
- New York Oncology Hematology - Albany Cancer Center /ID# 252240
-
Lake Success, New York, Estados Unidos, 11042
- Northwell Health - Monter Cancer Center /ID# 250422
-
Rochester, New York, Estados Unidos, 14642-0001
- University of Rochester Medical Center /ID# 249324
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45267-2827
- University of Cincinnati /ID# 249299
-
-
Oregon
-
Eugene, Oregon, Estados Unidos, 97401-6036
- Oncology Assoc. of Oregon PC - WVCI and Research Ctr - Springfield /ID# 249309
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania - Perelman Center for Advanced Medicine /ID# 250341
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030
- MD Anderson Cancer Center /ID# 249293
-
-
-
-
-
Paris, Francia, 75010
- Hopital Saint-Louis /ID# 253663
-
-
Gironde
-
Bordeaux, Gironde, Francia, 33000
- Institut Bergonie /ID# 253664
-
-
Herault
-
Montpellier, Herault, Francia, 34295
- CHU Montpellier - Hopital Saint Eloi /ID# 253666
-
-
Nord
-
Lille, Nord, Francia, 59037
- CHRU Lille - Hopital Claude Huriez /ID# 253665
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Francia, 44000
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 256248
-
-
Val-de-Marne
-
Villejuif, Val-de-Marne, Francia, 94805
- Institut Gustave Roussy /ID# 253662
-
-
-
-
Central District
-
Tsrifin, Central District, Israel, 70300
- Yitzhak Shamir Medical Center /ID# 254566
-
-
Jerusalem
-
Jerusalem, Jerusalem, Israel, 91120
- Hadassah Medical Center-Hebrew University /ID# 251123
-
-
Tel Aviv
-
Ramat Gan, Tel Aviv, Israel, 5265601
- The Chaim Sheba Medical Center /ID# 251122
-
Tel Aviv, Tel Aviv, Israel, 6423906
- Tel Aviv Sourasky Medical Center /ID# 259608
-
-
-
-
-
Bergamo, Italia, 24127
- Azienda Socio Sanitaria Territoriale Papa Giovanni XXIII /ID# 260317
-
Bologna, Italia, 40138
- IRCCS AOU di Bologna Policlinico Sant Orsola Malpighi /ID# 255172
-
-
Milano
-
Milan, Milano, Italia, 20132
- IRCCS Ospedale San Raffaele /ID# 253531
-
Milan, Milano, Italia, 20162
- ASST Grande Ospedale Metropolitano Niguarda /ID# 253532
-
-
Piedmont
-
Turin, Piedmont, Italia, 10126
- A.O.U. CITTA' DELLA SALUTE E DELLA SCIENZA DI TORINO - Ospedale Molinette /ID# 253530
-
-
-
-
Chiba
-
Kashiwa-shi, Chiba, Japón, 277-8577
- National Cancer Center Hospital East /ID# 250684
-
-
Kyoto
-
Kyoto, Kyoto, Japón, 606-8507
- Kyoto University Hospital /ID# 261837
-
-
Tokyo
-
Chuo-ku, Tokyo, Japón, 104-0045
- National Cancer Center Hospital /ID# 250680
-
Koto-ku, Tokyo, Japón, 135-8550
- The Cancer Institute Hospital Of Japanese Foundation for Cancer Research /ID# 260375
-
-
-
-
Cambridgeshire
-
Cambridge, Cambridgeshire, Reino Unido, CB2 2QQ
- Addenbrookes Hospital /ID# 256242
-
-
England
-
Leicester, England, Reino Unido, LE1 5WW
- Leicester Royal Infirmary /ID# 255171
-
-
Greater London
-
London, Greater London, Reino Unido, SE5 9RS
- Kings College Hospital NHS Foundation Trust /ID# 253670
-
London, Greater London, Reino Unido, NW1 2BU
- UCLH NHS FT - University College Hospital /ID# 260202
-
-
Criterios de participación
Criterio de elegibilidad
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
-
For Dose Escalation only (including backfill): Participants have received at least two prior systemic therapies, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), have measurable disease requiring treatment, and have a documented diagnosis for one of the following third line or later B-cell malignancies, from one of the following world health organization (WHO)-defined histologies (Swerdlow et al 2016):
-
Chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL)
- For Dose Escalation backfill only - Bruton's tyrosine kinase inhibitor (BTKi)/Bruton's tyrosine kinase degrader (BTKd)-naïve CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received at least one prior systemic therapy that cannot be a BTK inhibitor or degrader, and, with the exception of BTK pathway agents, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
- For Dose Escalation backfill only - BTKi/BCL-2i combination regimen-exposed 2L CLL/SLL. Participants with a documented diagnosis of CLL/SLL who have received one prior systemic therapy with a BTKi and BCL-2i combination regimen, have no available therapies known to provide clinical benefit (e.g., standard chemotherapy or HCT), and have measurable disease requiring treatment.
-
Chimeric antigen receptor T-cells (CAR-T)/hematopoietic cell transplant (HCT) relapsed/refractory (R/R) or ineligible diffuse large b-cell lymphoma (DLBCL) from the following histologies: DLBCL not otherwise specified (NOS) (germinal center B cell [GCB] and non-GCB DLBCL), T-cell/histiocyte-rich large B-cell lymphoma, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, anaplastic lymphoma kinase positive (ALK+) large B-cell lymphoma, high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements, and high-grade B-cell lymphoma NOS.
-
Mantle cell lymphoma (MCL)
-
Follicular lymphoma [FL] (grades 1-3b)
-
Marginal zone lymphoma [MZL] (splenic, extranodal, and nodal)
-
Waldenström macroglobulinemia (WM)
-
Transformed indolent non-Hodgkin's lymphoma (iNHL)
-
-
Has an Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) of 0, 1, or 2. For EU only: Participant has an ECOG PS of 0 or 1.
-
Participant has a life expectancy >= 12 weeks.
-
Prior Bruton's tyrosine kinase inhibitor (BTKi) is allowed.
-
Adequate hematologic, renal, and hepatic function per the protocol.
Exclusion Criteria:
- Previously treated with a Bruton's tyrosine kinase (BTK) degrader, except ABBV-101.
- Known active central nervous system (CNS) disease, or primary CNS lymphoma. Participants with prior CNS disease that have been effectively treated may be eligible.
- Uncontrolled active systemic infection requiring systemic treatment that is ongoing or was completed <= 14 days before the first dose of study drug, or active cytomegalovirus infection.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: N / A
- Modelo Intervencionista: Asignación de un solo grupo
- Enmascaramiento: Ninguno (etiqueta abierta)
Número de brazos
Armas e Intervenciones
Grupo de participantes/brazoGrupo de participantes/brazo |
Intervención / TratamientoIntervención / Tratamiento |
|---|---|
|
Experimental: Dose Escalation: ABBV-101
Participants with relapsed or refractory (R/R) Non-Hodgkin's lymphoma (NHL) will receive escalating doses of ABBV-101, until the maximum administered dose (MAD)/Maximum tolerated dose (MTD) is determined, as part of the approximately 88 month study duration. |
Oral:Tablet |
¿Qué mide el estudio?
Medidas de resultado primarias
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Number of Participants with Adverse Events (AE)
Periodo de tiempo: Up to Approximately 88 Months
|
AE is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 88 Months
|
|
Change in Laboratory Parameters
Periodo de tiempo: Up to Approximately 88 Months
|
Number of participants with clinically significant change from baseline in clinical laboratory test results like hematology will be reported. |
Up to Approximately 88 Months
|
|
Change in Vital Signs
Periodo de tiempo: Up to Approximately 88 Months
|
Number of participants with clinically significant change from baseline in vital signs like systolic and diastolic blood pressure will be reported. |
Up to Approximately 88 Months
|
|
Change in Electrocardiogram (ECG)
Periodo de tiempo: Up to Approximately 88 Months
|
12-lead resting ECGs will be recorded. Parameters include RR interval, PR interval, QT interval, and QRS duration. |
Up to Approximately 88 Months
|
Medidas de resultado secundarias
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Maximum Observed Serum Concentration (Cmax) of ABBV-101
Periodo de tiempo: Up to Approximately 88 Months
|
Maximum observed serum concentration of ABBV-101. |
Up to Approximately 88 Months
|
|
Time to Cmax (Tmax) of ABBV-101
Periodo de tiempo: Up to Approximately 88 Months
|
Time to Cmax of ABBV-101. |
Up to Approximately 88 Months
|
|
Area Under the Serum Concentration Versus Time Curve (AUC) of ABBV-101
Periodo de tiempo: Up to Approximately 88 Months
|
Area under the serum concentration versus time curve (AUC) of ABBV-101. |
Up to Approximately 88 Months
|
|
Number of Participants with Response of Partial Response (PR) or Better Response (Overall Response) per Disease-Specific Criteria
Periodo de tiempo: Up to Approximately 88 Months
|
Number of participants with response of PR or better response (overall response) per disease-specific criteria. |
Up to Approximately 88 Months
|
|
Duration of Response (DOR)
Periodo de tiempo: Up to Approximately 88 Months
|
DOR is defined for participants achieving PR or better as the time from the initial response per Investigator review to disease progression or death of any cause, whichever occurs earlier. |
Up to Approximately 88 Months
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Director de estudio: ABBVIE INC., AbbVie
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Inicio del estudio
Finalización primaria (Estimado)
Finalización primaria
Finalización del estudio (Estimado)
Finalización del estudio
Fechas de registro del estudio
Enviado por primera vez
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Publicado por primera vez
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización publicada
Última actualización enviada que cumplió con los criterios de control de calidad
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Última verificación
Más información
Términos relacionados con este estudio
Palabras clave
- Linfoma folicular (FL)
- Leucemia linfocítica crónica (LLC)
- Linfoma de linfocitos pequeños (SLL)
- Trasplante de células hematopoyéticas (TCH)
- Linfoma de células del manto (LCM)
- Linfoma de la zona marginal (MZL)
- Cáncer hematológico
- Células T receptoras de antígeno quimérico (CAR-T)
- Macroglobulinemia de Waldenström (WM)
- Linfoma no Hodgkin indolente transformado (INHL)
- ABBV-101
- Relapsed/refractory (R/R) or ineligible Diffuse large B-cell lymphoma (DLBCL)
Términos MeSH relevantes adicionales
- Enfermedades Vasculares
- Enfermedades cardiovasculares
- Procesos Patológicos
- Neoplasias por sitio
- Neoplasias
- Enfermedad crónica
- Atributos de la enfermedad
- Enfermedades del sistema inmunológico
- Neoplasias por tipo histológico
- Enfermedades hematológicas
- Enfermedades linfáticas
- Trastornos linfoproliferativos
- Trastornos inmunoproliferativos
- Linfoma No Hodgkin
- Leucemia de células B
- Linfoma de células B
- Linfoma
- Neoplasias De Células Plasmáticas
- Trastornos hemostáticos
- Paraproteinemias
- Trastornos de proteínas en sangre
- Trastornos hemorrágicos
- Leucemia Linfoide
- Leucemia
- Condiciones Patológicas, Signos y Síntomas
- Enfermedades hemic y linfáticas
- Reaparición
- Neoplasias Hematológicas
- Leucemia Linfocítica Crónica De Células B
- Linfoma Folicular
- Linfoma De Células Del Manto
- Macroglobulinemia de Waldenström
- Linfoma, Células B, Zona Marginal
Otros números de identificación del estudio
Otros números de identificación del estudio
- M23-647
- 2023 (Subvención/contrato del NIH de EE. UU.)
- 2023-503594-38-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .